

(b) *Tests and methods of assay*—(1) *Potency*—(i) *Nystatin content*. Proceed as directed in § 436.105 of this chapter, preparing the sample for assay as follows: Blend the entire contents of an accurately weighed representative portion of the sample for 3 to 5 minutes in a high-speed glass blender with sufficient dimethylformamide to give a convenient concentration. Dilute with sufficient dimethylformamide to yield a stock solution containing 400 units of nystatin per milliliter (estimated). Further dilute with 10 percent potassium phosphate buffer, pH 6.0 (solution 6), to the reference concentration of 20 units of nystatin per milliliter (estimated).

(ii) *Neomycin content*. Proceed as directed in § 436.105 of this chapter, preparing the sample for assay as follows: Blend an accurately weighed representative sample for 3 to 5 minutes in sufficient 0.1M potassium phosphate buffer, pH 8 (solution 3), to give a convenient concentration. Further dilute an aliquot with solution 3 to the reference concentration of 1 microgram of neomycin per milliliter (estimated).

(iii) *Gramicidin content*. Proceed as directed in § 436.106 of this chapter, preparing the sample for assay as follows: Dissolve an accurately weighed representative sample in alcohol U.S.P. XX and filter. Collect the filtrate and dilute a portion with alcohol U.S.P. XX to the reference concentration of 0.04 microgram of gramicidin per milliliter (estimated).

(2) *Loss on drying*. Proceed as directed in § 436.200(b) of this chapter.

[39 FR 19134, May 30, 1974, as amended at 41 FR 10886, Mar. 15, 1976; 47 FR 23710, June 1, 1982; 50 FR 19920, May 13, 1985]

#### § 449.550h Nystatin lotion.

(a) *Requirements for certification*—(1) *Standards of identity, strength, quality, and purity*. Nystatin lotion is composed of nystatin with one or more suitable and harmless suspending agents, emulsifiers, surfactants, and preservatives in a suitable and harmless vehicle. Each milliliter contains 100,000 units of nystatin. Its potency is satisfactory if it is not less than 90 percent and not more than 140 percent of the number of units of nystatin that it is represented to contain. Its pH is not less than 5.5

and not more than 7.5. The nystatin used conforms to the standards prescribed by § 449.50(a)(1).

(2) *Labeling*. It shall be labeled in accordance with the requirements of § 432.5 of this chapter.

(3) *Requests for certification; samples*. In addition to the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(a) The nystatin used in making the batch for potency, loss on drying, pH, and identity.

(b) The batch for potency and pH.

(ii) Samples required:

(a) The nystatin used in making the batch: 10 packages, each containing approximately 300 milligrams.

(b) The batch: A minimum of five immediate containers.

(b) *Tests and methods of assay*—(1) *Potency*. Proceed as directed in § 436.105 of this chapter, preparing the sample for assay as follows: Place an accurately measured representative portion of the sample into a high-speed glass blender jar containing sufficient dimethylformamide to give a convenient concentration. Blend for 3 to 5 minutes. Remove an aliquot and dilute with sufficient dimethylformamide to yield a stock solution containing 400 units of nystatin per milliliter (estimated). Further dilute with 10 percent potassium phosphate buffer, pH 6.0 (solution 6), to the reference concentration of 20 units of nystatin per milliliter (estimated).

(2) *pH*. Proceed as directed in § 436.202 of this chapter, using the undiluted sample.

[40 FR 3766, Jan. 24, 1975, as amended at 50 FR 19920, May 13, 1985]

### Subpart G—Vaginal Dosage Forms

#### § 449.610 Candididin vaginal dosage forms.

##### § 449.610a Candididin vaginal ointment.

(a) *Requirements for certification*—(1) *Standards of identity, strength, quality, and purity*. Candididin vaginal ointment is composed of candididin and a suitable ointment base. It contains 0.6 milligram of candididin per gram. Its

potency is satisfactory if it is not less than 90 percent and not more than 140 percent of the number of milligrams of candicidin that it is represented to contain. Its moisture content is not more than 0.1 percent. The candicidin used conforms to the requirements of § 449.10(a)(1).

(2) *Labeling.* It shall be labeled in accordance with the requirements of § 432.5 of this chapter.

(3) *Requests for certification; samples.* In addition to the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(a) The candicidin used in making the batch for potency, loss on drying, pH, and identity.

(b) The batch for potency and moisture.

(ii) Samples required:

(a) The candicidin used in making the batch: 10 packages, each containing approximately 300 milligrams.

(b) The batch: A minimum of five immediate containers.

(b) *Tests and methods of assay—(1) Potency.* Proceed as directed in § 436.106 of this chapter, preparing the sample for assay as follows: Place an accurately weighed representative portion of the sample into a separatory funnel containing approximately 50 milliliters of *n*-hexane (containing 0.1 percent butylated hydroxyanisole). Shake the sample and *n*-hexane until homogeneous. Add 15 milliliters of dimethylsulfoxide (containing 0.1 percent butylated hydroxyanisole) and shake well. Allow the layers to separate. Remove the bottom layer and repeat the extraction procedure with a second 15-milliliter portion of dimethylsulfoxide (containing 0.1 percent butylated hydroxyanisole). Combine the extractives in a suitable volumetric flask and fill to volume with sterile distilled water. Further dilute an aliquot with sterile distilled water to the reference concentration of 0.06 microgram of candicidin per milliliter (estimated).

(2) *Moisture.* Proceed as directed in § 436.201 of this chapter.

[39 FR 19134, May 30, 1974, as amended at 40 FR 15089, Apr. 4, 1975]

#### § 449.610b Candicidin vaginal tablets.

(a) *Requirements for certification—(1) Standards of identity, strength, quality, and purity.* Candicidin vaginal tablets are tablets composed of candicidin with suitable binders, diluents, and lubricants. Each tablet contains 3 milligrams of candicidin. Its potency is satisfactory if it is not less than 90 percent and not more than 150 percent of the number of milligrams of candicidin that it is represented to contain, except that for the issuance of a certificate for each batch, the candicidin content must be not less than 115 percent and not more than 150 percent of the number of milligrams of candicidin that it is represented to contain. The tablets shall disintegrate within 30 minutes. The loss on drying is not more than 1 percent. The candicidin used in making the batch conforms to the standards of § 449.10(a)(1).

(2) *Labeling.* The drug shall be labeled in accordance with the requirements of § 432.5 of this chapter.

(3) *Requests for certification; samples.* In addition to the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(a) The candicidin used in making the batch for potency, loss on drying, pH, and identity.

(b) The batch for potency, loss on drying, and disintegration time.

(ii) *Samples required.* (a) The candicidin used in making the batch: 10 packages, each consisting of approximately 300 milligrams.

(b) The batch: A minimum of 56 tablets.

(b) *Tests and methods of assay—(1) Potency.* Proceed as directed in § 436.106 of this chapter, preparing the sample for assay as follows: Weigh a pool of five tablets and grind in a mortar to a very fine powder. Suspend an accurately weighed aliquot (of approximately 2 grams) in 10 milliliters of dimethylsulfoxide. Centrifuge for 5 minutes at 2,000 revolutions per minute. Carefully decant the supernatant solution into a sterile 250-milliliter volumetric flask. Wash the residue three times with 5-milliliter portions of dimethylsulfoxide, centrifuging each time. Add the washes to the 250-milliliter volumetric flask